ABEONA THERAPEUTICS INC (ABEO:NASDAQ)
$6.01 -0.2 (-3.2206%)
Analysed ABEONA THERAPEUTICS INC (ABEO:NASDAQ) News Sources
Abeona Therapeutics Q2 Earnings Call Highlights
13-08-2026
marketbeat.com
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary
13-08-2026
moby.co
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone
21-08-2026
yahoo.com
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
04-08-2026
yahoo.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01-07-2026
yahoo.com
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
21-07-2026
yahoo.com
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
06-08-2026
yahoo.com
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
13-08-2026
yahoo.com
ABEO: Zevaskyn® Launch Gains Momentum
17-08-2026
yahoo.com
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...
17-08-2026
yahoo.com
What is the current price of ABEONA THERAPEUTICS INC (ABEO:NASDAQ)?
The current price of ABEONA THERAPEUTICS INC (ABEO:NASDAQ) is $6.01.
ABEONA THERAPEUTICS INC (ABEO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ABEONA THERAPEUTICS INC (ABEO:NASDAQ) since the previous trading day is $-0.2.
ABEONA THERAPEUTICS INC (ABEO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ABEONA THERAPEUTICS INC (ABEO:NASDAQ) since the previous trading day is -3.2206%.
What is the most recent average sentiment score for ABEONA THERAPEUTICS INC (ABEO:NASDAQ)?
The most recent average sentiment score for ABEONA THERAPEUTICS INC (ABEO:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for ABEONA THERAPEUTICS INC (ABEO:NASDAQ)?
The most recent sentiment for ABEONA THERAPEUTICS INC (ABEO:NASDAQ) is .
SEC-8K** Filing Available For ABEONA THERAPEUTICS INC (ABEO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.